liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins
Denver VA Medical Centre, CO 80220 USA; University of Colorado, CO 80202 USA.
F Hoffmann La Roche, Switzerland.
Pfizer Inc, NY USA.
Pfizer Inc, NY USA.
Show others and affiliations
2015 (English)In: Journal of the American College of Cardiology, ISSN 0735-1097, E-ISSN 1558-3597, Vol. 65, no 21, 2267-2275 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND Most patients with acute coronary syndrome (ACS) are treated with statins, which reduce atherogenic triglyceride-rich lipoproteins. It is uncertain whether triglycerides predict risk after ACS on a background of statin treatment. OBJECTIVES This study examined the relationship of fasting triglyceride levels to outcomes after ACS in patients treated with statins. METHODS Long-term and short-term relationships of triglycerides to risk after ACS were examined in the dal-OUTCOMES trial and atorvastatin arm of the MIRACL (Myocardial Ischemia Reduction with Acute Cholesterol Lowering) trial, respectively. Analysis of dal-OUTCOMES included 15,817 patients (97% statin-treated) randomly assigned 4 to 12 weeks after ACS to treatment with dalcetrapib (a cholesteryl ester transfer protein inhibitor) or placebo and followed for a median 31 months. Analysis of MIRACL included 1,501 patients treated with atorvastatin 80 mg daily beginning 1 to 4 days after ACS and followed for 16 weeks. Fasting triglycerides at initial random assignment were related to risk of coronary heart disease death, nonfatal myocardial infarction, stroke, and unstable angina in models adjusted for age, sex, hypertension, smoking, diabetes, high-density lipoprotein cholesterol, and body mass index. RESULTS Fasting triglyceride levels were associated with both long-term and short-term risk after ACS. In dalOUTCOMES, long-term risk increased across quintiles of baseline triglycerides (p less than 0.001). The hazard ratio in the highest/lowest quintile (greater than 175/less than= 80 mg/dl) was 1.50 (95% confidence interval: 1.05 to 2.15). There was no interaction of triglycerides and treatment assignment on the primary outcome. In the atorvastatin group of MIRACL, short-term risk increased across tertiles of baseline triglycerides (p = 0.03), with a hazard ratio of 1.51 (95% confidence interval: 1.05 to 2.15) in highest/lowest tertiles (greater than195/less than= 135 mg/dl). The relationship of triglycerides to risk was independent of lowdensity lipoprotein cholesterol in both studies. CONCLUSIONS Among patients with ACS treated effectively with statins, fasting triglycerides predict long-term and short-term cardiovascular risk. Triglyceride-rich lipoproteins may be an important additional target for therapy. (C) 2015 by the American College of Cardiology Foundation.

Place, publisher, year, edition, pages
Elsevier , 2015. Vol. 65, no 21, 2267-2275 p.
Keyword [en]
lipids; myocardial infarction; unstable angina
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-119573DOI: 10.1016/j.jacc.2015.03.544ISI: 000355196300001PubMedID: 26022813OAI: diva2:825326

Funding Agencies|F. Hoffmann-La Roche Ltd.; Pfizer; Anthera; Resverlogix; Roche; Sanofi; Amgen; AstraZeneca; Karobio; Merck

Available from: 2015-06-23 Created: 2015-06-22 Last updated: 2016-04-25

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Olsson, Anders
By organisation
Department of EndocrinologyFaculty of Medicine and Health SciencesDivision of Cardiovascular Medicine
In the same journal
Journal of the American College of Cardiology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 51 hits
ReferencesLink to record
Permanent link

Direct link